Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
Novacyt de volgende biotech raket!
Volgen
Kaspersky schreef op 3 maart 2020 14:50 :
Technisch: nog steeds in uptrend, steun op €1,15.
Kan met wat pessimisme gemakkelijk op €0,68 komen.
Nieuws: gevallen nemen toe, eind van deze week zal de schrik voor corona flink toe kunnen nemen.
Fundamenteel: nog steeds slecht -> alleen op te lossen met prijzen of aantallen x 10 of x 20. Vraag is hoe het bedrijf verder gaat zonder virus.
Anders: let op de ontwikkelingen, hier en daar wordt gesproken over samenwerking.
€1,33 nu.
Let's fight this virus :o) K
youtu.be/du0RVronhb4 In het kort: de ene test is beter dan de andere.
Clarice schreef op 3 maart 2020 13:38 :
Op het nieuwsblad.be wordt gemeld hoelang het duurt om je te testen en de kostprijs wordt vermeld.
Het testen gebeurt in twee keer! Een keer ongeveer 4 uur wachten en eventueel daarna weer eens 4 uur wachten. Kostprijs: ongeveer 20 euro.
Ben ik nu achterlijk of mis ik iets? De test van Novacyt duurt 2 uur en kost ongeveer 6 euro...
De belgische regering is een klucht...
Die verplegers en medisch personeel zijn ook niet gratis, 20 EUR ik vind dat heel goed meevallen.
@ Kasperski: Waar heeft u dat gelezen? dus in casu de samenwerking? DÁT kan interessant zijn...
--- om de een of andere reden kan ik geen berichten plaatsen --- zoek vooral nieuws -> er zijn positieve berichten Ps: ik heb geen aandelen Novacyt en in principe ook niet de intentie meer.
Kaspersky schreef op 3 maart 2020 14:50 :
Technisch: nog steeds in uptrend, steun op €1,15.
Kan met wat pessimisme gemakkelijk op €0,68 komen.
Nieuws: gevallen nemen toe, eind van deze week zal de schrik voor corona flink toe kunnen nemen.
Fundamenteel: nog steeds slecht -> alleen op te lossen met prijzen of aantallen x 10 of x 20. Vraag is hoe het bedrijf verder gaat zonder virus.
Anders: let op de ontwikkelingen, hier en daar wordt gesproken over samenwerking.
€1,33 nu.
Let's fight this virus :o) Dank. En wat is je beschouwing op het bericht van @Noob nr1 [3 maart 2020 12:38], waarvoor dank btw. Dat lijkt toch een redelijk positief nieuwsbericht?
goddijn50 schreef op 3 maart 2020 15:36 :
Lees op twitter approved
Wat is approved?
1,1 miljoen order van het bericht van noob 2,7 miljoen (verwachte) order van het bericht dat ik zojuist heb gelezen (levering Azië) Langzaam komen we nog wel ergens; ik hoop voor iedereen hier dat het succesvol wordt en blijft. ''It added that initial sales from this, which are subject to local emergency use approval, were anticipated to total 2.1 million pounds ($2.73 million) in the first six months of the agreement.'' 2 gebieden in Azië
Kaspersky schreef op 3 maart 2020 15:41 :
1,1 miljoen order van het bericht van noob
2,7 miljoen (verwachte) order van het bericht dat ik zojuist heb gelezen (levering Azië)
Langzaam komen we nog wel ergens; ik hoop voor iedereen hier dat het succesvol wordt en blijft.
Heeft u ook een bron die u wilt delen?
MovingUppppp schreef op 3 maart 2020 15:44 :
[...]
Heeft u ook een bron die u wilt delen?
Zoek maar op de tekst hierboven: ik wilde het hele artikel delen -> ERROR 500 in mijn scherm.
koers stijgt wel weer iets
Hmm zie nergens iets officieel bevestigd :(
By Peter Loftus and Brianna Abbott Testing for the new coronavirus in the U.S. may ramp up quickly after the Food and Drug Administration said it would speed approval of tests from hospital and public-health laboratories to augment the limited supply from the federal government. At a White House briefing Monday evening, FDA Commissioner Stephen Hahn said he expects the U.S. to have capacity for close to one million tests by the end of this week, from both public-health labs and private suppliers. "We've heard from multiple companies and multiple academic centers, and we expect to have a substantial increase in the number of tests, this week, next week and throughout the month," he said. Certain hospitals and health agencies around the country are working on their own diagnostics in addition to those in development from companies including Abbott Laboratories, Qiagen NV, Co-Diagnostics Inc. and bioMÃ?©rieux SA. Efforts to expand testing come as the illness caused by the virus spreads in the U.S., with new infections identified in people who hadn't traveled outside the country. More testing will be important to help allocate resources to the right patients, health officials say. Some other countries have already tested thousands of people but as of Saturday, about 470 people had been tested in the U.S. since Jan. 21, according to the Centers for Disease Control and Prevention's website, not including people who returned to the country on State Department- chartered flights. A quick expansion of testing could produce a sharp increase in the case count in the U.S., though that wouldn't necessarily indicate the virus is spreading at the same rate, experts say. "When you start giving diagnostic tests to people who never had them before you will almost certainly see an increase in declared cases," said Mark Miller, chief medical officer of French diagnostic-equipment maker bioMÃ?©rieux. "Whether that's a true increase or a detection bias, that has to be figured out on the local level." Initially developers of tests for coronavirus were required to obtain emergency FDA approval to ensure quality. The CDC test had been the only one approved for use in the U.S. Some CDC test kits sent to state labs didn't function properly, however, and many public health labs needed to wait for replacements. A handful of states had functioning CDC tests -- sometimes providing results within hours -- while others had to send their samples back to the CDC for results, a process that could take days. The agency has since ramped up test production and, facing pressure to expand testing quickly, federal authorities allowed state and local health departments to drop the part of their test kits that weren't working and move forward with the other components. Also, new test kits were manufactured and distributed. All positive diagnoses from the CDC-developed test, however, still need to be confirmed at the CDC's lab in Atlanta. The Department of Health and Human Services has said it launched an investigation into the manufacturing defect in the early CDC testing kits. The FDA now is allowing certified laboratories to develop and begin using new coronavirus tests while it reviews applications for approval. The FDA says these labs also have to follow certain guidelines aimed at ensuring the tests are valid. The FDA has communicated with more than 70 developers and public health labs working on their own tests, the agency says. Most tests for coronavirus world-wide use a technique called a real-time PCR, or polymerase chain reaction, a commonly used tool to look for pathogens by identifying unique parts of their genetic codes and amplifying them. The test can be used to diagnose a range of infections including influenza, and has been adapted to identify the genetic sequence of the new coronavirus. Specimens can be collected via swabs of nasal or pharyngeal fluids. The New York State Department of Health is testing coronavirus samples and providing hospitals with instructions to replicate the test in their own labs with the goal of providing roughly 1,000 tests a day. Hackensack Meridian Health, which operates 17 hospitals in northern New Jersey, began developing diagnostic assays several weeks ago, and now plans to make them available in the coming days, said David Perlin, chief scientific officer for Hackensack Meridian's Center for Discovery and Innovation. Hackensack Meridian's test can provide results in about two hours, and if positive, health-care workers could start treating a patient with supportive care while the specimen is sent to a state lab for confirmation. The hospital system could handle tests for about 50 to 100 patients a day if needed, but that capacity could be increased, Mr. Perlin said. Mr. Perlin said that if the virus spreads widely, experienced local labs will be needed -- in tandem with government labs -- to manage large-scale testing. Several companies are seeking federal regulatory approval for their coronavirus tests as well. BioMÃ?©rieux is developing two diagnostic tests for the new coronavirus, one of which is being developed under contract with the U.S. Department of Defense. That test delivers results for a single specimen within an hour and can be used outside of a lab if needed, such as at a border crossing or airport, said Mr. Miller, bioMÃ?©rieux's medical chief. The second test can run hundreds of specimens at a time but takes about four to five hours for results. The company expects to make the new tests available within the next several weeks, though regulatory approval could add to that timeline, Mr. Miller said. Germany's Qiagen is adding a test for the new virus to existing diagnostic equipment. It is being used in a handful of Chinese hospitals and the company is seeking to expand distribution to other countries. "We are now at the point where we need a decentralized solution that we can use more or less anywhere," Qiagen Chief Executive Thierry Bernard said in an interview. Abbott Labs plans to make a coronavirus test available on its molecular diagnostic instruments, which are used in labs around the world, and on tests that can be given in doctor's offices, a spokeswoman said. Salt Lake City-based Co-Diagnostics Inc. and San Diego-based Mesa Biotech also are developing tests for the new coronavirus. --Betsy McKay contributed to this article. Write to Peter Loftus at peter.loftus@wsj.com and Brianna Abbott at brianna.abbott@wsj.com (END) Dow Jones Newswires March 03, 2020 09:38 ET (14:38 GMT) © 2020 Dow Jones & Company, Inc. AAND ABBOTT LABORATORIES US0028241000 AAND BIOMERIEUX FR0013280286 AAND QIAGEN NV @ 0.01 DE NOT NL0012169213 CO DIAGNOSTICS INC COM USD0.001 US1897631057
MovingUppppp schreef op 3 maart 2020 15:44 :
[...]
Heeft u ook een bron die u wilt delen?
Alstu.www.pharmabiz.com/NewsDetails.aspx?ai...
De concurrentie is 'killing' voor Novaflut; dit wordt een rampzalige toestand en een grandioos verliesjaar voor dit bedrijfje. Als er 100 coronapatiënten zijn, worden er hoogstens 10 tot 20x mensen getest, kortom niet de moeite waard.
de zwarteridder heeft hier en punt
De zwarte ridder heeft waarschijnlijk net weer verkocht bij 1.40 en wil nu weer goedkoop instappen! Gewoon een dagtrader.. wat doe je hier anders heel de dag!
Novacyt, beter is er niet!
goddijn50 schreef op 3 maart 2020 16:12 :
De zwarte ridder heeft waarschijnlijk net weer verkocht bij 1.40 en wil nu weer goedkoop instappen! Gewoon een dagtrader.. wat doe je hier anders heel de dag!
Opvallend is dat niemand ontkent wat ik heb gezegd over het aantal testen dat nodig is.
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
CVC Capital Partners
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Premium
Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!
Word abonnee